TL;DR
The nasal GLDL spray is anticipated to be a promising and effective treatment option for BC by developing a nasal spray containing GCN-loaded liposomes (GLDL), and exhibited antiproliferative properties, as demonstrated by histopathological analysis of the formulation.
The outcomes of this research demonstrate the potential of PEGylated OLP-LNCs as an efficient nanocarrier for breast cancer treatment and improve its pharmacokinetic behavior after intravenous administration.
In an in vivo model of breast cancer, intraductal H-NPs reduced tumor incidence and volume compared to a drug solution, and increased the mammary tissue-to-plasma ratio of paclitaxel by 105-fold, supporting an improved tissue retention, support H-NPs as promising platforms for localized breast cancer therapy.
Delivery of gemcitabine using nanoparticles with dual responsiveness can significantly improve the antitumor activity and drug bioavailability and decrease systemic toxicity based on preclinical pharmacokinetic and biochemical evidence in a single xenograft model.
This review synthesizes recent high-impact literature on nanocarrier-mediated delivery of 5-FU for breast cancer, covering pharmacological considerations, nanocarrier classes, targeted and co-delivery approaches, stimuli-responsive designs, challenges to clinical translation, and emerging trends such as personalized na...
Histopathological and toxicity studies confirm the antiproliferative effects and safety of the transdermal LLT formulation and support the potential of transdermal LLT formulation to be an effective and safe treatment for BC.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
